GE HealthCare Technologies Inc.
GEHC.US Full Coverage
Last updated:
Volume
52W avg
Day Range
52W High
52W Low
Market Cap
Div Yield
Forward P/E
P/B
Headlines
FY2026 Q1
GE HealthCare cut its FY2026 adjusted EPS outlook to $4.80‑$5.00, down from $4.95‑$5.15, after identifying $250 million of new gross inflationary pressure from memory‑chip and logistics costs, and Q1 adjusted EPS of $0.99 missed guidance. Despite the warning, Q1 organic revenue rose 2.9% to the high end of expectations, supported by a 1.07× book‑to‑bill ratio and a record $21.8 billion backlog. The Patient Care Solutions segment continued to lag, with an 8.1% organic revenue decline.
FY2026 Adjusted EPS Guidance
$4.80 - $5.00
Lowered
Q1 Organic Revenue Growth
2.9%
High End of Guidance
Q1 Adjusted EBIT Margin
13.5%
-150 bps YoY
Flyrcado Weekly Doses
390
+77% since Jan-26
Total Backlog
$21.8B
+$1.2B YoY
What We're Watching
Risk
Inflation Impact vs. Mitigation Execution
📅
Q2-Q4 2026
What to Monitor
Management commentary on the realized inflation impact versus the projected $250M gross headwind. Evidence of price increases gaining traction on new orders and the successful implementation of cost actions in the second half of the year.
Why It Matters
The ability to meet the revised, lower guidance is entirely dependent on successfully offsetting over half of the new inflationary headwind. Failure to execute could lead to another downward revision and further damage forecast credibility.
Strategic / Risk
Patient Care Solutions (PCS) Strategic Review & Turnaround
📅
H2 2026
What to Monitor
Updates on the "strategic assessment of the portfolio." A return to positive organic growth and meaningful margin improvement in the second half, driven by large monitoring deals and the new anesthesia product launch.
Why It Matters
PCS remains a significant drag on corporate profitability and growth. The outcome of the strategic review could range from operational fixes to portfolio actions (divestiture), which would have a material impact on the company's long-term structure and margin profile.
Strategic
Advanced Imaging Solutions (AIS) Integration & Synergy Realization
📅
Q2 2026 Onward
What to Monitor
The recasted segment financials to be provided with Q2 reporting. Commentary on achieving the stated goals of sharpening disease-state focus, reducing costs, and accelerating growth from the new structure.
Why It Matters
This restructuring is management's primary strategic lever to drive long-term growth and efficiency. Successful integration is key to unlocking revenue synergies and cost savings that can help offset macro pressures and contribute to margin expansion targets.
Opportunity
Gadolinium-Free MRI Contrast Agent Clinical Progress
📅
Ongoing
What to Monitor
Positive data readouts from the combined Phase II/III study. Any updates on the FDA Fast Track designation and potential acceleration of the regulatory timeline from the stated 2029 launch target.
Why It Matters
This novel agent represents a significant, long-term growth opportunity that could disrupt the $1.2B MRI contrast market. Positive clinical progress would de-risk the pipeline and could be a major valuation catalyst, providing a powerful counter-narrative to near-term margin pressures.
Operational
Flyrcado (FERCATO) Dose Ramp Sustainability
📅
Q2-Q3 2026
What to Monitor
The ability to sustain or further accelerate weekly dose volumes beyond the 390-dose level. Commentary on scaling production at CMOs to support the onboarding of more high-volume sites.
Why It Matters
The strong Q1 ramp validated the "go slow to go fast" strategy. The next phase is crucial to demonstrate scalability and solidify the path to the $500M+ revenue target by 2028. Any stumbles in production could reignite concerns about execution risk.
